Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Armata Pharmaceuticals Gets $3.7M DoW Funding for AP-SA02

Armata Pharmaceuticals, Inc. filed a Form 8-K with the SEC on September 23, 2026, disclosing receipt of $3.7 million in additional non-dilutive funding from the U.S. Department of War to support Phase 3 development of its phage product candidate AP-SA02.

Nitish Kishor | 23 September 2026

Anteris Technologies Extends Supply Agreement with Harvey Industries

Anteris Technologies Global Corp. filed a Form 8-K on September 23, 2026, disclosing that its wholly owned subsidiary entered into an amendment extending an existing Supply and Quality Agreement with Harvey Industries Group Pty Ltd.

Shwetambri Chauhan | 23 September 2026

CytoSorbents Regains Nasdaq Bid Price Compliance, Faces Market Value Deficiency

CytoSorbents Corporation filed a Form 8-K on September 23, 2026, disclosing that it has regained compliance with Nasdaq's minimum bid price requirement while remaining out of compliance with the market value of listed securities requirement, with a deadline of December 28, 2026, to resolve …

Vinay Lochav | 23 September 2026

Beneficient Moves to Void Heppner Debt and Equity Ties

Beneficient filed a Form 8-K with the SEC on September 23, 2026, disclosing a strategy to eliminate debt it characterizes as fraudulently asserted by HCLP Nominees, L.L.C. and to remove equity interests held by former Chief Executive Officer Brad Heppner and his affiliated entities.

Nitish Kishor | 23 September 2026

Lantern Pharma Files 8-K on Open-Medicine AI Webinar

Lantern Pharma Inc. filed a Current Report on Form 8-K on September 23, 2026, disclosing a press release describing topics to be covered during a live webinar hosted by the company on September 23, 2026, focused on its Open-Medicine AI platform for drug development.

Aditi Sarkar | 23 September 2026

Valion Bio Appoints Dean Zikria as Interim CEO

Valion Bio, Inc. filed a Form 8-K with the SEC on September 23, 2026, disclosing the appointment of Dean Zikria as Interim Chief Executive Officer, a board resignation, and related committee changes, all effective as of September 17 or September 22, 2026.

Nitish Kishor | 23 September 2026

Lakeshore Acquisition III Moves to Nasdaq Capital Market

Lakeshore Acquisition III Corp. filed a Form 8-K on September 23, 2026, disclosing that Nasdaq approved its application to transfer its units, ordinary shares, and rights from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on September …

Shwetambri Chauhan | 23 September 2026

Adagio Medical Cuts 25 Jobs, Explores Strategic Alternatives

Adagio Medical Holdings, Inc. filed a Form 8-K with the SEC on September 23, 2026, disclosing a workforce reduction and the commencement of a strategic alternatives review process.

Aakashdeep | 23 September 2026

Astrana Health Reports Material Cybersecurity Incident

Astrana Health, Inc. filed a Form 8-K with the SEC on September 23, 2026, disclosing a material cybersecurity incident involving social engineering attacks against its subsidiary Astrana Health Management, Inc. that the company determined to be material as of September 22, 2026.

Shwetambri Chauhan | 23 September 2026

Beyond Meat Exchanges $15M in 2027 Notes for Common Stock

Beyond Meat, Inc. filed a Form 8-K on September 23, 2026, disclosing privately negotiated exchange agreements to retire approximately $15.0 million principal amount of its 0% Convertible Senior Notes due 2027 in exchange for shares of common stock.

Vinay Lochav | 23 September 2026
Support

Hi! How can we help you today?

Loading…